Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: A reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines

Stefano Omboni, Ettore Malacco, Jean Michel Mallion, Massimo Volpe

Research output: Contribution to journalArticlepeer-review

Abstract

In this paper, we present the results of a reanalysis of the data of two large randomized, double-blind, parallel group studies with a similar design, comparing the efficacy of an angiotensin-receptor blocker (olmesartan medoxomil) with that of an angiotensin-converting enzyme inhibitor (ramipril), by applying two different blood pressure targets recently recommended by hypertension guidelines for all patients, irrespective of the presence of diabetes (

Original languageEnglish
Pages (from-to)1575-1586
Number of pages12
JournalClinical Interventions in Aging
Volume10
DOIs
Publication statusPublished - Oct 1 2015

Keywords

  • Arterial hypertension
  • Elderly
  • Guidelines
  • Olmesartan medoxomil
  • Ramipril

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: A reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines'. Together they form a unique fingerprint.

Cite this